2024 Q2 Form 10-Q Financial Statement

#000112534524000088 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $10.80M $9.104M $10.72M
YoY Change -17.81% -62.83% -85.33%
Cost Of Revenue $176.0K $270.0K $163.0K
YoY Change -31.78% 138.94% -90.9%
Gross Profit $10.62M $8.834M $10.56M
YoY Change -17.53% -63.77% -85.2%
Gross Profit Margin 98.37% 97.03% 98.48%
Selling, General & Admin $14.42M $14.71M $12.56M
YoY Change 5.34% 8.74% -8.13%
% of Gross Profit 135.8% 166.5% 118.97%
Research & Development $51.73M $46.03M $47.35M
YoY Change 19.67% 0.34% 3.72%
% of Gross Profit 487.07% 521.04% 448.53%
Depreciation & Amortization $1.811M $1.841M $1.900M
YoY Change -35.6% -38.28% -41.19%
% of Gross Profit 17.05% 20.84% 18.0%
Operating Expenses $51.73M $46.03M $59.91M
YoY Change 19.67% 0.34% 0.99%
Operating Profit -$58.18M -$53.75M -$49.35M
YoY Change 29.4% 39.88% -511.87%
Interest Expense $6.000K $1.133M -$1.000K
YoY Change -99.22% -272.71%
% of Operating Profit
Other Income/Expense, Net $2.523M $2.693M $3.282M
YoY Change 10.9% 150.98% 300.73%
Pretax Income -$55.66M -$52.19M -$46.07M
YoY Change -196.86% 37.31% -459.89%
Income Tax
% Of Pretax Income
Net Earnings -$55.66M -$52.19M -$46.07M
YoY Change -196.86% 37.31% -459.88%
Net Earnings / Revenue -515.55% -573.26% -429.78%
Basic Earnings Per Share -$0.89 -$0.84
Diluted Earnings Per Share -$0.89 -$0.84 -$0.74
COMMON SHARES
Basic Shares Outstanding 62.63M shares 62.43M shares 62.03M shares
Diluted Shares Outstanding 62.66M shares 62.29M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.4M $184.2M $229.8M
YoY Change -41.6% -23.76% 48.89%
Cash & Equivalents $83.93M $80.36M $101.0M
Short-Term Investments $56.44M $103.9M $128.8M
Other Short-Term Assets $9.273M $9.871M $9.946M
YoY Change 43.21% 1.57% -2.12%
Inventory $1.115M $1.248M $1.221M
Prepaid Expenses $9.946M
Receivables $6.191M $7.219M $10.37M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $157.0M $202.6M $251.3M
YoY Change -38.37% -29.89% 13.12%
LONG-TERM ASSETS
Property, Plant & Equipment $20.38M $21.30M $45.69M
YoY Change -15.39% -20.49% 54.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.186M $1.185M $1.386M
YoY Change -14.43% -14.01% 0.58%
Total Long-Term Assets $44.19M $45.71M $47.08M
YoY Change -13.32% -16.21% -19.23%
TOTAL ASSETS
Total Short-Term Assets $157.0M $202.6M $251.3M
Total Long-Term Assets $44.19M $45.71M $47.08M
Total Assets $201.1M $248.3M $298.4M
YoY Change -34.19% -27.72% 6.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.236M $10.69M $6.443M
YoY Change 37.97% 184.49% 31.52%
Accrued Expenses $24.45M $18.15M $28.01M
YoY Change -11.2% -35.62% -3.39%
Deferred Revenue $23.82M $22.84M $21.65M
YoY Change 146.28% 146.91% 116.77%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $57.91M $55.76M $56.11M
YoY Change 28.24% 22.25% 15.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $258.0K $258.0K $89.70M
YoY Change 0.0% 0.0% 34666.28%
Total Long-Term Liabilities $258.0K $258.0K $89.70M
YoY Change 0.0% 0.0% 34666.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.91M $55.76M $56.11M
Total Long-Term Liabilities $258.0K $258.0K $89.70M
Total Liabilities $143.3M $142.1M $145.8M
YoY Change 6.87% -39.32% 5.31%
SHAREHOLDERS EQUITY
Retained Earnings -$1.211B -$1.155B -$1.103B
YoY Change 12.69% 2.05% 0.83%
Common Stock $1.268B $1.261B $1.255B
YoY Change 1.81% 1.63% 1.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $57.82M $106.2M $152.6M
YoY Change
Total Liabilities & Shareholders Equity $201.1M $248.3M $298.4M
YoY Change -34.19% -27.72% 6.4%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$55.66M -$52.19M -$46.07M
YoY Change -196.86% 37.31% -459.88%
Depreciation, Depletion And Amortization $1.811M $1.841M $1.900M
YoY Change -35.6% -38.28% -41.19%
Cash From Operating Activities -$44.49M -$45.64M -$28.04M
YoY Change 2029.49% 255.67% -195.62%
INVESTING ACTIVITIES
Capital Expenditures $1.035M $1.459M $620.0K
YoY Change 261.89% 306.41% 57.76%
Acquisitions
YoY Change
Other Investing Activities $48.47M $26.25M $39.44M
YoY Change -142.82% -7.74% -831.08%
Cash From Investing Activities $47.44M $24.79M $38.82M
YoY Change -141.8% -11.75% -770.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 625.0K $248.0K 273.0K
YoY Change 959.32% -99.75% -79.91%
NET CHANGE
Cash From Operating Activities -44.49M -$45.64M -28.04M
Cash From Investing Activities 47.44M $24.79M 38.82M
Cash From Financing Activities 625.0K $248.0K 273.0K
Net Change In Cash 3.577M -$20.60M 11.06M
YoY Change -103.1% -117.85% -55.57%
FREE CASH FLOW
Cash From Operating Activities -$44.49M -$45.64M -$28.04M
Capital Expenditures $1.035M $1.459M $620.0K
Free Cash Flow -$45.52M -$47.10M -$28.66M
YoY Change 1816.63% 257.05% -199.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Revenues
Revenues
9104000 usd
CY2023Q1 us-gaap Revenues
Revenues
24496000 usd
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
270000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
113000 usd
CY2024Q1 mgnx Cost Of Manufacturing Services
CostOfManufacturingServices
1846000 usd
CY2023Q1 mgnx Cost Of Manufacturing Services
CostOfManufacturingServices
3410000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46029000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45872000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14709000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13527000 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
62854000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
62922000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-53750000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-38426000 usd
CY2024Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2693000 usd
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1073000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
1133000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
656000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-52190000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38009000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-29000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
13000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52219000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37996000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62290538 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62290538 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61809817 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61809817 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
152613000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5512000 usd
CY2024Q1 mgnx Stock Issued During Period Value Stock Plan Activity
StockIssuedDuringPeriodValueStockPlanActivity
248000 usd
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-29000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
106154000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
142013000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4788000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
617000 usd
CY2023Q1 mgnx Stock Issued During Period Value Stock Plan Activity
StockIssuedDuringPeriodValueStockPlanActivity
-154000 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
13000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38009000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109268000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-52190000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-38009000 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1841000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2983000 usd
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1315000 usd
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
372000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5553000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4833000 usd
CY2024Q1 mgnx Non Cash Interest Expense Recognized
NonCashInterestExpenseRecognized
0 usd
CY2023Q1 mgnx Non Cash Interest Expense Recognized
NonCashInterestExpenseRecognized
656000 usd
CY2024Q1 mgnx Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
617000 usd
CY2023Q1 mgnx Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
941000 usd
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
90000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3148000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-20062000 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
27000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-42000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-75000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-443000 usd
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-201000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
4179000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-1148000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5891000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-677000 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
41000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-284000 usd
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1875000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2213000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45643000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12833000 usd
CY2024Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
50497000 usd
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
17296000 usd
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
76750000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
45750000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1459000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
359000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
24794000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28095000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
616000 usd
CY2024Q1 mgnx Proceedsfrom Stock Options Exercised And Espp Purchases
ProceedsfromStockOptionsExercisedAndESPPPurchases
2639000 usd
CY2023Q1 mgnx Proceedsfrom Stock Options Exercised And Espp Purchases
ProceedsfromStockOptionsExercisedAndESPPPurchases
5000 usd
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2391000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
158000 usd
CY2024Q1 mgnx Net Proceeds From Sale Of Future Royalties
NetProceedsFromSaleOfFutureRoyalties
0 usd
CY2023Q1 mgnx Net Proceeds From Sale Of Future Royalties
NetProceedsFromSaleOfFutureRoyalties
99655000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
248000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
100118000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20601000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
128855000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
128849000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
115380000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100956000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108884000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80355000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
224264000 usd
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
242000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
177000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
103917000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 usd
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
38000 usd
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
103882000 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M17D
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
209000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
261000 usd
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1039000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
960000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1248000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1221000 usd
CY2024Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1300000 usd
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3100000 usd
CY2017Q2 mgnx Share Based Compensation Arrangement By Share Based Payment Award Offering Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
P6M
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5553000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4833000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12223637 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.11
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1654555 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.99
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
257683 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.24
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
22343 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.04
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
23810 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
23.99
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13574356 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.54
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46445000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8150261 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.58
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
18242000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12411841 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.98
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
40279000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.17
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.77
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1900000 usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2600000 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3900000 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4400000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
34700000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001125345-24-000088-index-headers.html Edgar Link pending
0001125345-24-000088-index.html Edgar Link pending
0001125345-24-000088.txt Edgar Link pending
0001125345-24-000088-xbrl.zip Edgar Link pending
exhibit31-1q12024.htm Edgar Link pending
exhibit31-2q12024.htm Edgar Link pending
exhibit32-1q12024.htm Edgar Link pending
exhibit32-2q12024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgnx-20240331.htm Edgar Link pending
mgnx-20240331.xsd Edgar Link pending
mgnxexhibit10-1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mgnx-20240331_cal.xml Edgar Link unprocessable
mgnx-20240331_def.xml Edgar Link unprocessable
mgnx-20240331_lab.xml Edgar Link unprocessable
mgnx-20240331_pre.xml Edgar Link unprocessable
mgnx-20240331_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable